登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H9F3N2O2
化学文摘社编号:
分子量:
270.21
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
Leflunomide Related Compound B, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
SMILES string
O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1
InChI key
UTNUDOFZCWSZMS-YFHOEESVSA-N
grade
pharmaceutical primary standard
API family
leflunomide
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... DHODH(1723)
正在寻找类似产品? 访问 产品对比指南
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
General description
Leflunomide Related Compound B (2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)crotonamide is a malononitrilamide which is a water soluble metabolite of Leflunomide. It is considered as a noncompetitive inhibitor of dihydro-orotate dehydrogensae. This metabolite has been reported to initially target activated lymphocytes.
Other Notes
Sales restrictions may apply.
Titia E Vrenken et al.
Journal of hepatology, 49(5), 799-809 (2008-09-24)
Leflunomide is used in the treatment of autoimmune diseases as an anti-inflammatory agent. Leflunomide and its active metabolite A77 1726 modulate mitogen-activated protein kinases (MAPK), Src kinases, the phosphoinositide-3 kinase (PI3K)/Akt-pathway and nuclear factor (NF)-kappaB activation. Both cell protective and
Eva Bernhoff et al.
Journal of virology, 84(4), 2150-2156 (2009-12-04)
The immunomodulatory drug leflunomide is frequently used for treating polyomavirus-associated nephropathy, yet its antiviral mechanism is unclear. We characterized the effects of the active leflunomide metabolite A771726 (LEF-A) on the polyomavirus BK (BKV) life cycle in human renal tubular epithelial
Yu-cong Yuan et al.
Zhonghua yi xue za zhi, 91(10), 703-706 (2011-05-24)
To explore the therapeutic effects of leflunomide metabolite A771726 on high glucose-induced podocyte injury and understand its mechanism. The conditionally immortal human glomerular podocytes were divided into normal glucose group (NG), high glucose group (HG), mannitol group (MA), high glucose
Estrogens interfere with leflunomide modulation of cytokine production by human activated monocytes.
Paola Montagna et al.
Annals of the New York Academy of Sciences, 1193, 30-35 (2010-04-20)
Rheumatoid arthritis (RA) prevalence is greater in females than in males, supporting estrogens as modulators of immune response. Leflunomide (LEF) is employed in the RA treatment. We studied the combinatory effects of LEF active metabolite A77 1726 (LEF-M) and 17beta-estradiol
Takeo Sato et al.
Rheumatology (Oxford, England), 48(10), 1265-1268 (2009-08-05)
To elucidate the factors associated with poor prognosis of LEF-induced lung injury in patients with RA. The background and clinical and laboratory features of LEF-induced lung injury were examined and compared between patients who died of and who recovered from
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持